本帖最后由 老马 于 2013-3-13 13:43 编辑 2 \# M( b1 o3 Y3 G) F
. H* v" a; d/ S! o健择（吉西他滨）+顺铂+阿瓦斯汀
7 L6 C+ y' B' \; D! K, X4 c$ t. W: [5 x Gemzar +Cisplatin + Avastin
7 g9 D4 R8 ~: `http://annonc.oxfordjournals.org/content/21/9/1804.full' _, S' a4 B+ C
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
& Y* R3 B2 Z( e1 FPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
5 @1 c' x: ]" L! l/ [. J* r$ yResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
5 ~) W3 k0 Y1 \8 x" j7 U
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 898)
1 h3 y1 X( V4 |9 ?! H
华为网盘附件：; L5 h; m9 S3 H" O
【华为网盘】ava.JPG4 f. X# @# `( ]8 D& W: Y
|
晚期肺癌13年靶向轮换之路，我总结9
讲述者：不怕辣椒不怕癌整理者：雪漓
上篇文章中分享了我家13年抗癌经历以及心态成长
无靶点 her2扩增 二线白紫耐药后怎么
家父今年62岁，22年11月份颈部淋巴结穿刺，确诊肺低分化腺癌，分期是TxN3M1，基因检测
全球首个！肺癌新靶向药获批，客观缓
作者：seacat
2025年6月30日，中国国家药品监督管理局（NMPA）附条件批准伯瑞替尼用于
聚焦2025 ASCO 前列腺癌新进展，从循
作者：Tony男人一旦上了年纪，总有些难以启齿的尴尬，如尿频、尿急、尿不尽……很多人
20前插+Pik3ca，请教各位战友、老师
肺腺癌iVb期，首次基因检测发现是20前插+Pik3ca，ki-67 10%~20%。
刚刚进行了一次培美
显身卡
